A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
EpicentRx, Inc.
Incyte Corporation
Canadian Cancer Trials Group
Critical Outcome Technologies Inc.
Roswell Park Cancer Institute
Scripps Health